Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Thoracic 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 205pembrolizumab 169Pemetrexed 144Cisplatin 126Paclitaxel 78durvalumab 75osimertinib 70Nivolumab 68Docetaxel 66Specimen Handling 64atezolizumab 60Magnetic Resonance Spectroscopy 54Etoposide 47Gemcitabine 46Radiotherapy 45Radiosurgery 40130-nm albumin-bound paclitaxel 36Drug Therapy 33Bevacizumab 29Cetuximab 28Ipilimumab 27cemiplimab 25Taxes 24tislelizumab 21Immunoglobulin G 21Radiation 20Platinum 20Biopsy 20amivantamab 19Disulfides 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pevonedistat × Thoracic × 90 days × Clear all
NCT03965689 2026-04-13

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

National Cancer Institute (NCI)

Phase 2 Active not recruiting
27 enrolled 13 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡